Frequency and clinical consequences of extremely high maternal serum PAPP-A levels

Prenatal Diagnosis

Volumn 23, Issue 5, 2003, Pages 385-388

  Cuckle, H ^a   Arbuzova, S ^b   Spencer, K ^c   Crossley, J ^d   Barkai, G ^e   Krantz, D ^f   Muller, F ^g   Nikolenko, M ^b   Aitken, D ^d   Hallahan, T ^f   Macri, J ^f   Buchanan, P D ^h  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b Interregional Medico Genetics Centre   (Ukraine)

^c HAROLD WOOD HOSPITAL   (United Kingdom)

^d ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^e GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^f NTD Laboratories   (United States)

^g HÔPITAL AMBROISE PARÉ   (France)

^h GeneCare Medical Genetics Center   (United States)

Author keywords

Down syndrome; Extremely high; Maternal serum; PAPP A; Screening

Indexed keywords

PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ARTICLE; CLINICAL TRIAL; DISEASE MARKER; DOWN SYNDROME; FEMALE; FETUS ECHOGRAPHY; GASTROSCHISIS; GROWTH RETARDATION; HUMAN; MAJOR CLINICAL STUDY; MATERNAL BLOOD; MATERNAL HYPERTENSION; MULTICENTER STUDY; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY DIABETES MELLITUS; PRENATAL SCREENING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; DOWN SYNDROME; FEMALE; HUMANS; MASS SCREENING; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS;

EID: 0037903475     PISSN: 01973851     EISSN: None     Source Type: Journal    
DOI: 10.1002/pd.600     Document Type: Article

References (19)

1. Aranguren G, Garcia-Minaur S, Loridan L, Uribarren A, Vargas LM, Rodriguez-Soriano J. 1996. Multiple-marker screen positive results in Noonan syndrome. Prenat Diagn 16: 183, 184.
2. Bersinger NA, Zakher A, Huber U, Pescia G, Schnelder H. 1995. A sensitive enzyme immunoassay for pregnancy associated plasma protein A: a possible first trimester method of screening for Down syndrome and other trisomies. Arch Gynecol Obstet 256: 185-192.
3. Brambati B, Lanzani A, Tului L. 1991. Ultrasound and biochemical assessment of the first-trimester pregnancy. In The Embryo: Normal and Abnormal Development and Growth, Chapman M, Grudzinskas G, Chard T (eds). Springer-Verlag: Berlin; 181-194.
4. Bueler MR, Bersinger NA. 1989. Antiserum to pregnancy associated plasma protein A (PAPP-A) recognizes human haptoglobin. Br J Obstet Gynaecol 96: 867-869.
5. Cuckle HS, Sehmi IK, Jones R, Mason G. 1999. Low maternal serum PAPP-A and fetal viability. Prenat Diagn 19(8): 788-790.
6. Dawood MY. 1976. Circulating maternal progesterone in high-risk pregnancies. Am J Obstet Gynecol 125: 832-840.
7. de Graaf IM, Cuckle HS, Pajkrt E, Leschot NJ, Bleker OP, Van Lith JMM. 2000. Co-variables in first trimester maternal serum screening. Prenat Diagn 20: 186-189.
8. Hurley PA, Ward RHT, Teisner B, Iles RK, Lucas M, Grudzinskas JG. 1993. Serum PAPP-A measurements in first-trimester screening for Down's syndrome. Prenat Diagn 13: 903-908.
9. Krantz DA, Hallahan TW, Orlando F, Buchanan P, Larsen JW, Macri JN. 2000. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet Gynecol 96: 207-213.
10. Nisbet DL, Griffin DR, Chitty LS. 1999. Prenatal features of Noonan syndrome. Prenat Diagn 19: 642-647.
11. Ong CYT, Liao AW, Spencer K, Munim S, Nicolaides KH. 2000. First trimester maternal serum free β human chorionic gonadotropin and pregnancy-associated plasma protein A as predictors of pregnancy complications. Br J Obstet Gynaecol 107: 1265-1270.
12. Ruge S, Pedersen JF, Sorensen S, Lange AP. 1990. Can pregnancy-associated plasma protein A (PAPP-A) predict the outcome of pregnancy in women with threatened abortion and confirmed fetal viability? Acta Obstet Scand 69: 589-595.
13. Schmidt D, Rose E, Greenberg F. 1993. An association between fetal abdominal wall defects and elevated levels of human chorionic gonadotropin in mid-trimester. Prenat Diagn 23: 9-12.
14. Smith GCS, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. 2002. Early pregnancy levels of pregnancy associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia and stillbirth. J Clin Endocrinol Metab 87: 1762-1767.
15. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. 1999. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 13: 231-237.
16. Spencer K, Ong CYT, Liao AWJ, Nicolaides KH. 2000. The influence of parity and gravidity on first trimester markers of chromosomal abnormality. Prenat Diagn 20: 792-794.
17. Tsukerman GL, Gusina NB, Cuckle HS. 1999. Maternal serum screening for Down's syndrome in the first trimester: experience from Belarus. Prenat Diagn 19: 499-504.
18. Westergaard JG, Sinosich MJ, Bugge M, Madsen LT, Teisner B, Grudzinskas JG. 1983. Pregnancy-associated plasma protein A in the prediction of early pregnancy failure. Am J Obstet Gynecol 145: 67-69.
19. Wheeler DM, Sinosich MJ. 1998. Prenatal screening in the first trimester of pregnancy. Prenat Diagn 18: 537-543.